If you want more than just a prescription mailed to your door, this model may fit your preferences
Semaglutide 2.4 mg (Wegovy), a once-weekly GLP-1 receptor agonist licensed by the MHRA and recommended by NICE (Technology Appraisal TA875) for use in specific circumstances, demonstrated mean weight loss of approximately 14.9% from baseline at 68 weeks in the STEP 1 phase 3 trial (Wilding JPH et al., N Engl J Med
Keep in mind that many cats will not show an improvement in health
Approximately 82 to 88% of trial participants completed the study without discontinuing due to side effects
Where Hexarelin Fits in the GH Ecosystem Hexarelin occupies a specific niche in the growth hormone research landscape: Strongest acute GH secretagogue in the GHRP class Only GHRP with robust cardiac research (CD36-mediated, GH-independent) Highest side-effect burden among GHRPs (prolactin, cortisol, desensitization) Best suited for combination protocols where its dose can be lowered via GHRH synergy Poor choice for long-term continuous use due to receptor downregulation For most GH research, Ipamorelin paired with CJC-1295 is the more practical combination cleaner side-effect profile, less desensitization, and still meaningful GH elevation
